The United Kingdom and the United States have reached a major commercial pact that will guarantee zero import taxes on UK medicine exports being sold in the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on pharmaceuticals through the National Health Service (NHS). This pledge ensures that import taxes on these crucial goods will remain at zero for a timeframe of the next three years.
This deal comes after recent statements to dramatically increase import taxes on patented drug products, with potential rates floated as high as one hundred percent.
"This arrangement with the United Kingdom bolsters the international landscape for cutting-edge drugs and establishes much-needed fairness to American-British medicine commerce," a release said.
Commercial Impact
Drugs are one of the the United Kingdom's biggest export categories to the America, which is easily the primary destination for leading UK drugmakers.
Trade data reveal that in the one-year period leading up to the third quarter, the UK shipped medicines valued at over eleven billion pounds to the US. This value made up 17.4% of total UK exports in that timeframe.
"This deal protects employment, increases capital expenditure and sets the stage for the UK to emerge as a international leader for medical research," a government official commented.
Detailed UK Commitments
The pact involves several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new treatments to be too expensive by 25%.
- Boosted Medicine Funding: There is a target to increase overall health service expenditure on medicines from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage manufacturers must refund to the NHS to prevent overspending will be capped at 15%. Previously, refunds exceeded 20%.
Broader Context
The pact follows a protracted row between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
These tensions were heightened by claims that American consumers were paying a premium for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or abandoned, while substantial expansions have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had declined as a proportion of its total funding over the past decade.
